Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
January 8, 2015
Policymakers should be wary of adverse side effects when promoting competition for short-term consumer welfare.
January 7, 2015
New evidence demonstrates that IPRs have not decreased access to medicines.
April 10, 2014
To remain a leader in medical innovation, U.S. must strengthen research and IP.
March 17, 2014
What if innovation in life sciences stopped? A new study on Swedish healthcare provides insight.
March 14, 2014
The Potentially Deleterious Impacts of the President’s FY 2015 Budget on U.S. Life Sciences Industries
The President's FY 2015 budget should do more to promote the innovation capacity and competitiveness of U.S. life sciences industries.
December 1, 2013
The TPP will only be worth it if it concludes with an innovation-maximizing trade agreement that sets the standard for future trade deals for the U.S.
July 8, 2013
Better use of data analytics can help us make better predictions and fewer errors.
December 5, 2012
Further evidence that debunks the myth that pharmaceutical companies aren't providing real value to the economy.
October 2, 2012
Rob Atkinson will present at FTC workshop "Competition & Consumer Protection Issues in the Pet Medications Industry"
September 12, 2012
Non-partisan report evaluates the candidates' positions on innovation-based policy.